Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 3

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Authors Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

Published 12 September 2008 Volume 2008:3(3) Pages 445—451

DOI http://dx.doi.org/10.2147/CIA.S2046

Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Greece

Abstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.

Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Erratum

Xiao N, Shi S, Zhuang H

Hepatic Medicine: Evidence and Research 2011, 3:19-20

Published Date: 18 March 2011

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes

Magnus Dencker, Martin Stagmo, Mozhgan Dorkhan

Vascular Health and Risk Management 2010, 6:373-382

Published Date: 18 May 2010

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer

Catherine Oakman, Marta Pestrin, Elena Zafarana, et al

Cancer Management and Research 2010, 2:13-25

Published Date: 7 January 2010

Venous and arterial thrombosis: Two aspects of the same disease?

Paolo Prandoni

Clinical Epidemiology 2009, 1:1-6

Published Date: 12 January 2009

Pathophysiology of placentation abnormalities in pregnancy-induced hypertension

Mitsuko Furuya, Junji Ishida, Ichiro Aoki, Akiyoshi Fukamizu

Vascular Health and Risk Management 2008, 4:1301-1313

Published Date: 5 December 2008

Single photon emission computed tomography: An alternative imaging modality in left ventricular evaluation

Hulya Yalçin, Sofiane Maza, Fatih Yalçin

Vascular Health and Risk Management 2008, 4:1069-1072

Published Date: 10 October 2008